IQVIA Holdings Inc. $IQV Shares Sold by New York State Teachers Retirement System

New York State Teachers Retirement System decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 0.4% in the second quarter, HoldingsChannel.com reports. The firm owned 146,433 shares of the medical research company’s stock after selling 605 shares during the quarter. New York State Teachers Retirement System’s holdings in IQVIA were worth $23,076,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Clal Insurance Enterprises Holdings Ltd increased its stake in IQVIA by 436.7% during the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock worth $28,000 after buying an additional 131 shares in the last quarter. Golden State Wealth Management LLC increased its stake in IQVIA by 295.5% during the 1st quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock worth $31,000 after buying an additional 130 shares in the last quarter. AllSquare Wealth Management LLC purchased a new stake in IQVIA during the 1st quarter worth approximately $33,000. Trust Co. of Toledo NA OH purchased a new stake in IQVIA during the 2nd quarter worth approximately $39,000. Finally, J.Safra Asset Management Corp increased its stake in IQVIA by 208.6% during the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock worth $39,000 after buying an additional 169 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analyst Ratings Changes

Several research firms have commented on IQV. William Blair reiterated an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. HSBC upgraded IQVIA from a “hold” rating to a “buy” rating and upped their price target for the company from $195.00 to $235.00 in a research report on Thursday, October 9th. Truist Financial upped their price target on IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Hsbc Global Res upgraded IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. Finally, Robert W. Baird increased their price objective on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 23rd. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $234.57.

IQVIA Trading Down 0.6%

Shares of IQVIA stock opened at $204.51 on Friday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a 50 day moving average of $191.41 and a 200 day moving average of $169.23. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $237.21. The firm has a market capitalization of $34.77 billion, a price-to-earnings ratio of 29.60, a PEG ratio of 2.26 and a beta of 1.32.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping analysts’ consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The company had revenue of $4.02 billion for the quarter, compared to analysts’ expectations of $3.96 billion. During the same period in the prior year, the firm earned $2.64 earnings per share. The firm’s revenue was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insiders Place Their Bets

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the company’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the transaction, the insider directly owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the company’s stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. 1.60% of the stock is owned by corporate insiders.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.